Treatment of peripheral T cell lymphoma

Patent metadata

Field	Value
Publication number	US-10344087-B2
Application number	US-201414767600-A
Country	US
Kind code	B2
Filing date	Feb 13, 2014
Priority date	Feb 14, 2013
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

First claim

The invention claimed is:

1. A method for treating an enteropathy associated T cell lymphoma (EATL) in an individual, the method comprising identifying an individual having refractory celiac disease (RCD) and EATL and administering to the individual a therapeutically active amount of an anti-NKp46 antibody that binds an NKp46 polypeptide and depletes NKp46-expressing tumor cells and said anti-NKp46 antibody is linked to a toxic agent.

2. A method for treating an enteropathy associated T cell lymphoma (EATL) in an individual comprising:
a) obtaining malignant cells from an individual having RCD and EATL,
b) detecting prominent expression of NKp46 polypeptide on the surface of the malignant cells, and
c) administering to the individual an anti-NKp46 antibody that binds an NKp46 polypeptide, said anti-NKp46 antibody is linked to a toxic agent.

3. The method of claim 1 , wherein the antibody comprises an amino acid modification that enhances binding to a human Fcγ receptor.

4. The method of claim 3 , wherein the variant Fc region comprises an amino acid substitution at one or more of positions 221, 239, 243, 247, 255, 256, 258, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 300, 301, 303, 305, 307, 308, 309, 310, 311, 312, 316, 320, 322, 326, 329, 330, 332, 331, 332, 333, 334, 335, 337, 338, 339, 340, 359, 360, 370, 373, 376, 378, 392, 396, 399, 402, 404, 416, 419, 421, 430, 434, 435, 437, 438 and/or 439.

5. The method of claim 4 , wherein the variant Fc region comprises a substitution at one or more of positions 239, 298, 330, 332, 333 and/or 334.

6. The method of claim 5 , wherein said one or more amino acid substitutions are S239D, S298A, A330L, I332E, E333A and/or K334A.

7. The method of claim 6 , wherein said one or more amino acid substitutions are S239D, S298A, A330L, I332E, E333A and K334A.

Assignees

• Innate Pharma

Inventors

• Bonnafous Cécile
• Sicard Hélène
• Buffet Renaud
• Blery Mathieu

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N2333/70503

  Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title